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Herpes simplex virus (HSV) most frequently initiates infection at a mucosal surface; thus mucosal immune responses are
likely to be important in defense against HSV infection. We have examined the effects of eliciting mucosal as well as systemic
immune responses on protection against genital challenge infection with virulent HSV-2 in mice immunized with a replication-
defective mutant of HSV-2. In addition, we have examined the types of immune responses elicited by immunization by the
different routes under conditions known to provide protection. We observed that immunizations at parenteral and distal
mucosal sites generate immune responses that have an additive effect in protection against challenge infection with virulent
HSV-2. Immunization at either of these sites alone prevented paralysis and death after challenge virus infection and reduced
replication of the challenge virus in the genital mucosa, although subcutaneous immunization was more effective in reducing
virus replication. Simultaneous immunization at the two sites led to the greatest reduction in mucosal replication of challenge
virus. The type of response generated was also affected by the route of immunization. Subcutaneous immunization results
in a strong systemic immune response that is somewhat biased toward a Th1 T cell response, while intranasal immunization
induces mucosal as well as systemic immunity, as evidenced by HSV-specific IgA in vaginal secretions, and a stronger bias
toward a Th1 response. These results suggest that mucosal immunization may complement protective immunity against
HSV-2 genital infection generated by parenteral immunization with replication-defective mutant virus. © 1998 Academic Press
INTRODUCTION
Many human pathogens enter and replicate at a mu-
cosal surface before causing systemic infection. For
pathogens that have the capacity to persist in an infected
individual, it is particularly important to curtail infection at
the mucosal surface before persistent infection of sys-
temic sites of latency or chronic infection is initiated.
HSV infection of the oral or genital mucosa generates a
mucosal immune response with IgA and IgG present in
genital secretions (Ashley et al., 1994a,b). This primary
infection via the mucosa renders individuals at least
partially resistant to infection by a second, heterologous
strain (Mertz et al., 1992). These observations suggest
that mucosal immune responses may be an important
component of host defense against HSV, and their induc-
tion in addition to systemic immune responses may in-
crease the efficacy of prophylactic vaccination.
Systemic immunization typically does not elicit muco-
sal immune responses (McDermott et al., 1990), although
mucosal immunization with HSV can elicit modest sys-
temic immunity (Irie et al., 1992; McDermott et al., 1990;
Milligan and Bernstein, 1995a). Induction of mucosal
immune responses by immunization of the genital tract
with subsequent protection from genital challenge gen-
erally has proven effective only with replicating virus
(Milligan and Bernstein, 1995a; McDermott et al., 1984);
intravaginal (i.vag.) immunization with HSV glycoprotein
D (gD) in adjuvant is inefficient (Drew et al., 1992). These
observations suggest that the genital mucosa, which
lacks organized lymphoid accumulations (Parr et al.,
1994), may be a poor immune induction site. The genital
tract can also be populated with memory cells by infec-
tion or immunization of distant mucosae (McDermott and
Bienenstock, 1979; Haneberg et al., 1994) and distal
immunization can elicit immune responses in the genital
tract of greater magnitude than i.vag. immunization
(Haneberg et al., 1994). Individuals with HSV-1 infection
of the oral mucosa have HSV-specific IgA present in
genital secretions (Ashley et al., 1994a) and mount
anamnestic responses to subsequent genital HSV infec-
tion (Ashley et al., 1994a). In a mouse model, intranasal
(i.n.) immunization with a replication-competent adenovi-
rus vector expressing HSV gB has been shown to protect
against genital challenge with HSV (Gallichan and
Rosenthal, 1995).
HSV mutant strains defective for essential viral func-
tions constitute a vaccine approach that stimulates
broad spectrum immune responses to numerous HSV
gene products without the risks associated with attenu-
ated virus vaccines. These mutant viruses are live but
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genetically compromised for some step of infectious
progeny virus production. Mutants containing a deletion
in the ICP8 gene essential for viral DNA replication are
truly defective for spread in a vaccinated host in that they
can neither replicate their DNA nor produce progeny
virions (Gao and Knipe, 1989). We have previously shown
that parenteral immunization of guinea pigs with a rep-
lication-defective mutant of HSV-2, 5BlacZ, decreases
severity of genital lesions, replication of HSV-2 challenge
virus in the genital mucosa, and the incidence of recur-
rent disease (Da Costa et al., 1997). The observation that
a replication-defective HSV-1 mutant stimulates immune
responses of nearly the same magnitude and duration as
those stimulated by immunization with the wild-type pa-
rental strain (Morrison and Knipe, 1996) suggested that
these viruses would elicit immune responses if inocu-
lated via the mucosa as well. Support for this conjecture
has come from a second type of HSV mutant defective for
an essential viral function, the single cycle gH2 mutant
(Farrell et al., 1994). This mutant virus undergoes a round
of replication in the host, but the virions produced are
defective for entry into new cells. Intraepithelial immuni-
zation with an HSV-1 gH2 mutant can reduce primary
lesion scores and incidence of recurrent infection in a
guinea pig model of genital infection with HSV-2
(McLean et al., 1994). In addition, i.n. immunization with
this gH2 HSV-1 mutant has been shown to protect
guinea pigs against HSV-2 genital challenge more effec-
tively than the i.vag. route (McLean et al., 1996). However,
because gH2 mutants undergo a round of replication
and likely dissemination in the host, the capacity to
immunize a mucosal surface with replication-defective
mutants was by no means certain.
We sought to determine whether immunization with a
replication-defective mutant of HSV-2 is efficacious in
protecting mice from genital challenge infection with
HSV-2 and whether immunization of a distal mucosal
surface with this mutant would elicit a mucosal immune
response in the genital tract. We hypothesized that, un-
der conditions of protective immunity generated by im-
munization with replication-defective HSV-2, the exis-
tence of mucosal as well as systemic immune responses
would augment protection of the genital mucosa. We
therefore chose the intranasal route for distal mucosal
immunization and compared primary replication of chal-
lenge virus and protection against disease under condi-
tions of mucosal, systemic, or combined mucosal and
systemic immune responses. Second, we determined
the type of helper T cell response associated with mu-
cosal and systemic routes of immunization. Third, we
examined the importance of live virus to effective muco-
sal immunization under circumstances where de novo
synthesis of viral proteins in the mucosa and simple
exposure of the mucosa to viral proteins can be com-
pared. Answers to these questions will help to define the
parameters by which effective immunization against HSV
infection may be achieved.
RESULTS
We chose a mouse model of genital infection with
HSV-2 (Bourne et al., 1996; Parr et al., 1994) because the
inbred mouse model provides a large number of immu-
nological reagents for analysis of protective immune
mechanisms generated by mucosal and parenteral im-
munization with replication-defective mutants of HSV-2.
Our mutant virus, 5BlacZ, has been engineered from the
186 strain of HSV-2 (Da Costa et al., 1997); thus, as a
heterologous challenge virus we used the virulent HSV-2
strain G (Larica et al., 1968), a limited passage clinical
isolate. I.vag. inoculation of 105–106 PFU of G virus by
this protocol resulted in inflammation in the genital area
and genital lesions by 5 days postinfection of naive mice.
Infectious virus was shed from the genital tract for at
least 7 days and ascending paralysis followed, leading to
death of the animals between 8 and 15 days postinfec-
tion. Dose studies demonstrated that the LD50 of HSV-2
G inoculated i.vag. into BALB/c mice was 104 PFU (data
not shown). This mouse model system was used to
evaluate the capacity of the 5BlacZ HSV-2 replication-
defective mutant to induce protective immunity and the
effect of mucosal immunization on the resulting immune
response and subsequent protection against genital in-
fection.
Protection from genital infection by mucosal
immunization with replication-defective virus
To determine the ability of immunization by distal muco-
sal or parenteral routes to protect against genital challenge,
we immunized mice twice at 1-month intervals with 5BlacZ
or control lysate of uninfected cells by i.n. or subcutaneous
(sc) routes or by simultaneous i.n. and sc administration of
virus such that the total dose of virus was the same in all
cases. One month later, all groups were challenged i.vag.
with HSV-2 strain G. Primary replication of challenge virus
in the genital mucosa was reduced in mice immunized by
any route with the replication-defective virus compared with
mice inoculated with control cell lysate (Fig. 1). Mice immu-
nized sc with the replication-defective virus had signifi-
cantly lower titers of virus shed from the vaginal mucosa
beginning 1 day after challenge and had nearly resolved
the infection by day 3 (Fig. 1B). Mice immunized i.n. did not
show a significant decrease in titer compared to control
mice until more than 3 days after challenge. However, they,
too, had resolved mucosal infection by 5 days after chal-
lenge, when the titer of virus in control mice was still .103
PFU/sample (Fig. 1A). The combination of i.n. and sc ad-
ministration of virus resulted in the most dramatic reduc-
tions of primary replication in the genital tract, with a
peak titer on day 1 postchallenge of only 10 PFU/sample
(Fig. 1C).
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Mice immunized sc or i.n./sc with 5BlacZ were com-
pletely protected from development of local genital le-
sions and exhibited no signs of systemic disease, even
though the dose of challenge virus represented approx-
imately 50 LD50. Mice immunized i.n. with 5BlacZ were
protected from development of genital disease, showing
only mild and transient signs of genital inflammation and
ruffled fur at days 5–7 postchallenge (Fig. 2). In contrast,
100% of mice in all control groups developed severe
genital lesions and hind limb paralysis (Fig. 2) and even-
tually succumbed to the challenge infection (Fig. 3). In-
terestingly, mice immunized i.n. with 5BlacZ and then
infected i.vag. developed zosteriform lesions beginning
approximately 8 days after challenge, suggesting that the
immune response generated in i.n.-immunized mice is
not sufficient to protect them from infection of peripheral
sensory neurons innervating the genital tract.
FIG. 1. Titers of HSV-2 challenge virus shed from the vaginal mucosa
of mice immunized by different routes. Groups of five mice were
immunized twice at 1-month intervals with mutant virus or control cell
lysate by i.n. (A), sc (B), or simultaneous i.n. and sc routes (C) and then
challenged i.vag. Vaginal swabs were collected at the indicated times
postchallenge and titered by standard plaque assay. Values represent
the mean 6 SEM for each group. Data are from one representative
experiment of four.
FIG. 2. Immunization with replication-defective virus promotes sur-
vival of mice after lethal i.vag. challenge with HSV-2. Mice were immu-
nized twice with 5BlacZ or control lysate by the indicated route and
monitored over time for survival after i.vag. challenge with approxi-
mately 50 LD50 HSV-2 G. Survival in groups of mice immunized with
5BlacZ was 100% regardless of the immunization route. Data are from
the same experiment described in Fig. 1 (1 of 4 experiments).
FIG. 3. Incidence of genital and neurologic disease in mice immu-
nized with 5BlacZ by different routes. Groups of five mice were immu-
nized twice at 1-month intervals with mutant virus (5B) or control cell
lysate (CL) by the indicated routes, challenged 1 month after the
second immunization, and observed daily thereafter for signs of clinical
disease. Scores were given to individual mice based on the 5-point
system described under Materials and Methods. Data points, repre-
senting mean score 6 SEM for each group, are from the same exper-
iment described in Fig. 1 (1 of 4 experiments).
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Antibody responses in mice after mucosal or
systemic immunization
We determined the serum neutralizing antibody titers and
HSV-specific IgG ELISA titers in stored sera from the same
group of mice challenged above. Mice immunized sc or
i.n./sc had equivalently robust neutralizing antibody re-
sponses 16 days after the second immunization (Table 1,
Experiment 1). Serum antibody neutralization titers in mice
immunized i.n. with 5BlacZ were below the level of detec-
tion, suggesting that the protective effect of i.n. immuniza-
tion was independent of serum neutralizing antibody. Fur-
thermore, simultaneous i.n. administration of immunizing
virus did not significantly boost systemic antibody titers
elicited by sc antigen administration. HSV-specific IgG was
detectable by ELISA in serum of i.n.-immunized mice, but
was still very low compared with mice immunized sc or
i.n./sc (Table 1, Experiment 1). In a separate experiment,
HSV-specific antibodies in the vaginal secretions of mice
immunized i.n. or sc were evaluated as a measure of the
mucosal response to immunization. Vaginal wash samples
were collected from mice 21 days after the second immu-
nization with 5BlacZ and tested by quantitative ELISA for
the presence of HSV-specific IgA and IgG (Table 1, Exper-
iment 2). While i.n. immunization with 5BlacZ again elicited
only low levels of HSV-specific serum IgG, virus-specific
IgA was found in the vaginal wash samples (and in fecal
samples in equivalent amounts; data not shown). This con-
trasts with the antibody response to sc immunization with
5BlacZ, which consisted of high titers of IgG in the serum
and very low levels of IgG and no detectable IgA in vaginal
wash samples.
Serum antibody responses following sc immunization
with the HSV-1 ICP82 mutant, d301, show a relatively
high ratio of IgG2a to IgG1 characteristic of a Th1 type of
response to either HSV or HSV-encoded b-galactosidase
(b-gal) (Brubaker et al., 1996). We asked whether immu-
nization with replication-defective virus via the nasal
mucosa would also elicit a Th1-like response or would
resemble the Th2 type of response that prevails after
mucosal immunization with protein antigens. Surpris-
ingly, mice that had been immunized i.n./sc had a higher
serum IgG2a to IgG1 ratio than mice immunized sc with
5BlacZ (Table 2, Experiment 1), indicating an augmenta-
tion of the systemic Th1 response with simultaneous
mucosal administration of mutant HSV. Although the total
IgG response in the serum of mice immunized i.n. was
much lower, the IgG2a to IgG1 ratio was skewed still
further in the direction of a Th1 response. The relation-
ship between the HSV-specific IgG2a to IgG1 ratios was
maintained in a second experiment comparing mice im-
munized with 5BlacZ by sc or i.n. routes (Table 2, Exper-
iment 2). The antibody response to virus-encoded b-gal
in these same sets of sera also was examined to permit
comparison with sera from mice immunized sc with b-gal
in alum as a Th2 control. An exaggerated Th1 type
response to virus-encoded b-gal again was observed in
i.n.-immunized mice (Table 2, bottom). Taken together,
these observations using IgG isotype ratios as a surro-
gate marker for Th responses indicate that mucosal
immunization with replication-defective virus exagger-
ates the disposition toward a Th1 response seen after
parenteral immunization and suggests that immunization
with live but replication-defective virus stimulates im-
mune responses through active infection rather than
mere exposure to viral protein antigens.
Requirement of live virus for induction of the mucosal
antibody response
We assessed whether active infection with de novo
expression of viral proteins in infected cells indeed plays
an important role in the stimulation of immune responses
by mucosal immunization with replication-defective vi-
rus. Use of replication-defective virus for mucosal immu-
nization likely limits exposure more precisely to mucosal
TABLE 1
HSV-Specific Serum and Secretory Antibodies in Immunized Mice






Vaginal wash ELISA titer (ng/ml)
IgG IgA
1b Control sc ,4 n.d.c
5BlacZ i.n. ,4 5 6 2
5BlacZ sc 9.8 980 6 300
5BlacZ in/sc 9.8 530 6 160
2d Control i.n. ,0.02 ,0.02 ,0.3
5BlacZ i.n. 11 6 4 0.02 6 0.02 6.2 6 1.5
5BlacZ sc 1790 6 380 0.35 6 0.15 ,0.3
a Determined by CPE inhibition assay.
b Serum for Experiments 1 and 2 collected 16 and 20 days after second immunization, respectively.
c Not determined.
d Data are representative of three experiments.
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tissues than would be possible with replication-impaired
virus (because no progeny virus is produced), and use of
partially purified virus stocks eliminates the immunizing
potential of infected cell proteins. Mice were immunized
twice i.n. with partially purified live or UV-inactivated
5BlacZ, a partially purified tk2 mutant of HSV-2 (positive
control), or an equivalent preparation from uninfected
cells (negative control), and the quantity of IgG in serum
and IgA in vaginal washes was determined by ELISA.
Immunization with live 5BlacZ generated IgA in vaginal
washes and a low titer of IgG in serum (Fig. 4). Titers of
both IgG and IgA were lower than that seen with the tk2,
replication-competent control virus but strongly con-
trasted with mice immunized with UV-5BlacZ, whose
titers all were below the level of detection. These results
suggest that the capacity to infect cells and synthesize
viral proteins is an integral component of stimulation of
mucosal as well as systemic immunity using replication-
defective virus.
DISCUSSION
In this work we have shown that immunization of mice
with a replication-defective HSV-2 mutant virus indepen-
dently at parenteral or mucosal sites generates comple-
mentary immune responses whose protective effects are
apparently additive when elicited together. Subcutane-
ous immunization led to a strong systemic immune re-
sponse that is somewhat biased toward a Th1 T cell
response, while intranasal immunization induced muco-
sal immunity, as evidenced by IgA in vaginal secretions,
and a stronger bias toward a systemic Th1 response.
Immunization at either of these sites alone could prevent
paralysis and death after challenge virus infection and
reduce genital replication of challenge virus, although
subcutaneous immunization was more effective in re-
ducing virus replication. Simultaneous immunization at
the two sites led to the greatest reduction in challenge
virus infection, suggesting that the types of immune
responses induced by the two routes of immunization
are additive in terms of protecting the genital mucosa.
Finally, our data indicate that viral gene expression in
mucosal cells infected by live, replication-defective virus
is essential to the immune inductive capacity of the
mutant virus.
Determination of the types of vaccine-induced immune
responses that protect against virus infection is impor-
tant to the design and implementation of any effective
vaccine strategy. Immune responses generated by par-
enteral immunization with replication-impaired viruses
have previously been shown to protect against systemic
HSV-1 infection (Farrell et al., 1994; Nguyen et al., 1992)
and corneal challenge (Morrison and Knipe, 1996, 1994)
in mice and to reduce replication and disease associ-
ated with HSV-2 infection of the genital tract in guinea
pigs (McLean et al., 1994; Da Costa et al., 1997). Immune
responses generated by mucosal immunization of
guinea pigs with a single cycle gH2 mutant reduces
lesion incidence and severity but does not significantly
alter primary replication of challenge virus in the mucosa
(McLean et al., 1996; Boursnell et al., 1997). I.vag. and
TABLE 2
IgG Isotype Ratio in Sera of Mucosally Immunized Mice
Experiment No. Immunization group




1 5BlacZ sc 4.36 6 1.07 5.99 6 0.34 0.02
5BlacZ in/sc 3.85 6 0.15 4.67 6 0.10 0.15
5BlacZ i.n. 2.17 6 0.24 3.35 6 0.09 0.07 (3.5x)b
2c 5BlacZ sc 1.51 6 0.11 2.93 6 0.05 0.04
5BlacZ i.n. 2.87 6 0.09 3.07 6 0.13 0.62 (15.5x)
Control i.n. u.d.d u.d.
b-Gal-specific antibodies
1 5BlacZ sc 5.56 6 0.21 6.53 6 0.20 0.11
5BlacZ in/sc 5.13 6 0.12 5.82 6 0.20 0.20
5BlacZ i.n. 3.40 6 0.64 3.93 6 0.45 0.30 (2.7x)
2 5BlacZ sc 4.44 6 0.38 5.04 6 0.13 0.25
5BlacZ i.n. 3.42 6 0.24 2.72 6 0.71 5.04 (20.2x)
Control i.n. u.d. u.d.
b-Gal/alum sc 5.72 6 0.22 7.19 6 0.21 0.04
a Sera were collected 21 days after the second immunization and analyzed by ELISA.
b Fold increase in IgG2a/IgG1 ratios in i.n.-immunized mice compared with sc.
c Data are representative of four experiments.
d Undetectable.
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peroral routes of immunization are inferior to i.n. for both
gH2 single cycle (McLean et al., 1996) and ICP82 repli-
cation-defective (L. Morrison, unpublished observation)
mutants. Comparison of i.vag. and sc routes of immuni-
zation with HSV-1 or HSV-2 single cycle mutants re-
vealed that the parenteral route provides more signifi-
cant protection of the mucosa (Boursnell et al., 1997;
McLean et al., 1994). Our study is the first to assess the
immune protection afforded by simultaneous mucosal
(i.n.) and parenteral (sc) immunization. We found that
mucosal immunization is not interchangeable with par-
enteral immunization. Sc immunization clearly gave su-
perior protection in that mice showed no adverse clinical
signs after challenge and had lower titers of challenge
virus in the genital tract compared to mice immunized i.n.
alone. Even a single sc immunization with 5BlacZ lowers
primary titers and protects against disease (Da Costa et
al., in preparation). Nevertheless, it should be empha-
sized that i.n. immunization was able to significantly
affect primary replication and development of disease
even at the high challenge dose (50 LD50) of HSV-2 strain
G used in these experiments. Intranasal immunization
contributed a mucosal immune response that parenteral
immunization did not induce, as evidenced by sIgA in the
genital tract. Notably, the systemic antibody response
was lower in mice immunized i.n./sc than in those im-
munized sc, yet i.n./sc immunization afforded equivalent
protection from disease and greater reduction of chal-
lenge virus replication in the genital mucosa. Our data
suggest that i.n. immunization could be used to enhance
the protective immunity generated by sc immunization.
Whether simultaneous administration by i.n. and sc
routes is optimal for induction of systemic and mucosal
immune responses is a matter for further exploration.
All routes of immunization reduced primary replication
to some extent in the genital mucosa, suggesting that
preexisting immune effectors may act within the mucosa
itself. The rapidity with which replication-defective virus-
immune mice reduced challenge virus replication sup-
ports this contention. The immune components stimu-
lated by replication-defective virus that provide protec-
tion of the genital tract at each stage of infection remain
to be determined, but these issues can be readily ad-
dressed in the mouse model of genital HSV infection.
The precise contribution of sIgA to protection may be
difficult to assess, however, because of known compen-
satory mechanisms in mice genetically deficient in IgA
production.
Antibody responses to the replication-defective mu-
tants were monitored as an indicator of immune stimu-
lation and type of Th response. They may correlate with
level of protection but are not necessarily responsible for
protection. Ab
0/0 (MHC class II2) mice have been used to
demonstrate the dependence of glycoprotein vaccine-
induced protection on immune responses restricted by
MHC class II (Ghiasi et al., 1997). Our work identifying
immune subsets elicited by replication-defective virus
that are protective against HSV-1 infection of the cornea
indicate an important contribution of T cells and in par-
ticular CD41 cells (Morrison and Knipe, 1997). Moreover,
the data of Milligan and Bernstein (1995b) argue that
memory CD41 T cells of the Th1 type are likely the
important defenders of the genital tract against HSV
infection, an interpretation that fits with our observation
of a Th1-like antibody response. One role of CD41 Th1
cells is provision of help for IgG2a production, but the
observation that IFNg produced by CD41 T cells is re-
quired for rapid virus clearance from the genital tract
(Milligan and Bernstein, 1997) indicates another role for
the Th1 cytokine that could explain in large part the
importance of Th1 responses to protection.
Although the titer of IgG in the serum of mice immu-
nized by the i.n. route was low, the high ratio of IgG2a:
IgG1 clearly indicated induction of a Th1-like systemic
antibody response when virus is administered muco-
sally. Indeed, to our knowledge, this is the first indication
that mucosal immunization can bias the systemic im-
mune response even further toward a Th1 response than
what is seen with parenteral immunization of virus. A
Th1-like response induced via the mucosa contrasts with
the prevailing view of Th2-mediated help for antibody
production, at least in the gastrointestinal mucosa (Oka-
hashi et al., 1996; Fujihashi et al., 1993). Our data are
consistent, however, with observations on mucosal
(lung) immunization or infection with influenza (Tomoda
FIG. 4. HSV-specific antibody titers in serum and vaginal washes of
mice immunized with different forms of virus. Groups of three to four
mice were immunized twice with supernatant preparations of live or
UV-inactivated 5BlacZ virus, its attenuated (tk2) parental strain
186tkDKpn, or control supernatant and then were challenged i.vag. with
HSV-2 G. Virus-specific serum IgG and vaginal wash IgA titers were
determined by ELISA of samples collected 21 days after the second
immunization and 7 days after challenge, respectively. Data represent
geometric mean titers 6 SEM of a single experiment. Asterisks indi-
cate titers significantly different from those of the live 5BlacZ-immu-
nized group. One of 4 samples in the CS group was anomalously high;
3 of 4 were below the level of detection.
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et al., 1995) or infection of the gastrointestinal mucosa
with recombinant salmonella (VanCott et al., 1996). One
interpretation of these findings is that a fundamental
difference exists between mucosal immune stimulation
by protein antigen and whole, infectious organisms that
may actively stimulate cytokines and/or chemokines that
lead to a Th1 type of systemic response. Alternatively,
types of antigen presenting cells predominating at differ-
ent mucosal surfaces may influence the type of T cell
help induced at each and consequently the type of sys-
temic response detected. If i.n. immunization with repli-
cation-defective HSV-2 also exaggerates the Th1-like na-
ture of responses in the genital mucosa, this could be a
mechanism whereby i.n./sc immunization resulted in the
greatest reduction of challenge virus replication in the
genital mucosa, exclusive of a contribution by sIgA.
The serum antibody response to b-gal also clearly
indicated a ratio of IgG2a:IgG1 consistent with a Th1-like
response, in contrast to the Th2-like response elicited by
sc immunization with b-gal in alum. A Th1-like response
to b-gal had been seen previously upon parenteral im-
munization with replication-defective virus (Brubaker et
al., 1996), and we have now shown this to be true after
i.n. immunization as well. These results suggest that
proteins expressed in the context of HSV infection will
elicit immunity dominated by cell-mediated responses
even though they would by themselves elicit a more
humoral Th2 response, whether the response initiates
systemically or at a mucosal surface. Thus, replication-
defective mutants of HSV may be useful as a vector for
stimulation of immune responses to foreign proteins
whenever cell-mediated responses are desirable.
Our results with i.n. immunization are similar to those
with single cycle gH2 virus (McLean et al., 1996) in that
a stronger mucosal IgA response was observed after
immunization with live replication-defective virus than
with UV-inactivated, replication-defective virus. This ob-
servation suggests that live virus is important to the
inductive capacity of replication-impaired mutants. How-
ever, our results differ in that we observed (1) a very low
systemic IgG response with live virus immunization, (2)
little IgG transudate in vaginal wash samples, and (3) no
systemic or mucosal antibody response after immuniza-
tion with UV-inactivated 5BlacZ. gH2 virus may stimulate
a greater systemic response after mucosal immunization
due to dissemination into the systemic circulation of
noninfectious progeny virions from the basolateral sur-
faces of infected mucosal cells. The distribution of
5BlacZ, on the other hand, may remain much more lo-
calized to the mucosa since no progeny virus is pro-
duced. Efficient stimulation of systemic immunity may, in
turn, be necessary to generate enough IgG to detect as
transudate. Regarding the third difference, i.n. immuni-
zation with inactivated gH2 virus may have elicited a
weak mucosal response because of the much larger
quantity of infected cell proteins in the whole cell lysate
that was used or because of incomplete virus inactiva-
tion. Against this backdrop, lack of response to i.n. im-
munization with partially purified, UV-inactivated 5BlacZ
clearly demonstrated that active infection and not mere
antigen uptake is required to promote immune re-
sponses to replication-defective virus introduced via the
mucosa. Whether use of live virus promotes immune
responses through endogenous presentation of newly
synthesized viral proteins in infected cells or simply by
increasing the amount of total viral protein is not known.
The importance of mucosal responses to protection
against genital HSV infection remains to be established.
However, any mechanism that would enhance the num-
bers of HSV-specific memory cells in genital lymph
nodes and tissues could be expected to enhance the
host’s preparedness to meet a genital challenge with
HSV-2 and curtail infection before virus can enter the
nervous system. Gallichan has demonstrated virus-spe-
cific ASC in the tract after i.n. immunization with an
adenovirus vector expressing HSV gB (Gallichan and
Rosenthal, 1996), and McDermott has demonstrated the
protective capacity of HSV-immune T cells derived from
genital but not distal lymph nodes to protect against
genital challenge (McDermott et al., 1989). A combination
of parenteral and mucosal immunization with replication-
defective virus may optimize induction of memory cells
that home to the genital tract to provide maximum de-
fense against challenge. Elucidation of mechanisms
whereby mucosal immune responses are induced may
be best answered through the use of the truly replication-
defective mutants where immune induction is more likely
to be confined to mucosal tissues and regional lymph
nodes with little systemic response. Thus, replication-
defective virus may prove useful as a tool for investigat-
ing immune responses to HSV at the mucosa and their
importance as a defense mechanism, as well as poten-
tially constituting a safe and effective vaccine strategy.
MATERIALS AND METHODS
Cells and viruses
5BlacZ, a replication-defective mutant of HSV-2, strain
186syn1, is defective in the UL29 gene encoding ICP8
due to insertion of the lacZ gene (Da Costa et al., 1997).
A replication-competent, thymidine kinase-negative (tk2)
mutant of strain 186syn1, 186DKpn, has also been con-
structed (Taylor, Jones, and Knipe, unpublished results).
Stocks of tk2 virus were prepared by growth in Vero
cells, and 5BlacZ by growth in S-2 (Gao and Knipe, 1989)
or V8-27 cells [stably transfected with the UL29 and UL54
genes; (Da Costa et al., 1997)] in Medium 199 supple-
mented to contain 1% FCS by standard methods (Morri-
son and Knipe, 1996). HSV-2 strain G is a limited passage
clinical isolate (Larica et al., 1968). Supernatant virus
stocks were prepared from infected cell cultures that
were frozen and thawed once. Cells were removed by
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low-speed centrifugation, and then virions in the super-
natant were pelleted by centrifugation at 25,000g for 1 h
at 4°C. Virus pellets were resuspended in a small vol-
ume of Medium 199 supplemented with 1% normal
mouse serum, sonicated, and stored at 280°C. Control
supernatant was prepared from frozen and thawed, un-
infected cell cultures. A portion of the supernatant virus
stock of 5BlacZ was inactivated by exposure to UV light
as previously described (Morrison and Knipe, 1994), re-
sulting in .6 log10 reduction in titer.
Mice and inoculations
Female BALB/c mice, purchased from Taconic Labo-
ratories and the National Cancer Institute, were housed
and cared for in accordance with PHS (Anonymous,
1985) and institutional guidelines and used at 7 weeks of
age. For i.n. immunization, mice were anesthetized with
nembutal (0.07 mg/g body wt) and 1 3 105–1 3 106 PFU
in a 2.5-ml volume per nostril of virus or control prepa-
ration was applied with a pipette tip. For sc immuniza-
tion, unanesthetized mice were injected in the hind flank
with 2 3 106 virus or control preparation in 20-ml volumes
using a 1-ml syringe fitted with a 26-gauge needle. For
simultaneous i.n./sc immunization, 1 3 106 PFU was
applied to one nostril and 1 3 106 PFU was injected in
the flank. Immunizations were repeated after 4 weeks,
and mice were challenged 4 weeks after the second
immunization. Seven days and 1 day prior to challenge,
mice were injected sc in the neck ruff with depoprovera
(3 mg per mouse in a 100-ml volume). For i.vag. chal-
lenge, mice were anesthetized, preswabbed with a type
1 calcium alginate swab (Spectrum), and inoculated with
5 3 105 PFU of HSV-2 strain G (approximately 50 LD50) in
5-ml volumes using a pipette tip.
Assay of acute infection
Ten hours and 1–5 days postchallenge, vaginal muco-
sae of mice were swabbed with two successive swabs.
The swabs were placed together into vials containing 1
ml assay medium (PBS plus glucose and 1% FCS) and
stored at 280°C. Viral titers were determined by stan-
dard plaque assay (Morrison and Knipe, 1996).
Clinical observations
Mice were observed daily for signs of genital lesions
and systemic illness. The severity of disease was scored
as follows: 0, no sign; 1, slight genital erythema and
edema; 2, moderate genital inflammation; 3, purulent
genital lesions; 4, hind-limb paralysis; 5, death.
Serum collection and vaginal washes
Blood was collected from tail veins 3 weeks after
primary immunization and 2–3 weeks after secondary
immunization. Serum was prepared as previously de-
scribed (Morrison and Knipe, 1994). Vaginal washes
were performed at the time of serum collection by thrice
titurating 25 ml PBS in the vaginal vault using a pipette
tip. Washes were pooled, bestatin and 4-(2-aminoethyl)-
benzenesulfonyl fluoride (Sigma) were added to a final
concentration of 0.2 mM and 3.25 mM, respectively, and
samples were frozen at 220°C.
Antibody neutralization assay and quantitative ELISA
Virus neutralization assays were carried out as previ-
ously described, except that HSV-2 G was used as the
virus strain to be neutralized. A quantitative ELISA was
developed by a modification of the technique of Zollinger
and Boslego (Zollinger and Boslego, 1981). In brief, quan-
titation standards were established by titration of a pos-
itive control serum (pooled from mice immunized with
HSV-2) on Immunlon 2 plates (Dynatech) coated with
HSV-2 G lysate (Advanced Biotechnologies) in parallel
with purified IgG and IgA (Sigma) or IgG1 and IgG2a (gift
of P. Yaciuk) titrated on Maxisorp plates (Nunc) coated
with goat anti-Kappa light chain (Caltag). OD values of
positive control serum dilutions in the range of 1 to 2
units were used to determine antibody concentration by
comparison to the purified antibody concentration
curves. A dilution series of this positive control serum
was then run in each assay to generate a standard curve
for comparison of serum or vaginal wash samples. Goat
anti-mouse IgG and IgA conjugated to biotin (Caltag)
were used as secondary antibodies for assays of IgG
and IgA, followed by addition of streptavidin–HRP (Sig-
ma). HRP-conjugated goat anti-mouse IgG1 and IgG2a
(Southern Biotechnologies) were used in isotype-specific
assays. All assays were developed by addition of OPD
(Sigma) for 30 min and then read at OD490. Disparity
between total and subtype-specific serum IgG titers (Ta-
bles 1 and 2) is attributable to use of sera from different
experiments and to different sources of standards. Total
antibody concentrations were determined by capture
ELISA using anti-Kappa-coated plates.
Statistical analyses
Significance of the difference in vaginal wash titers
was determined by comparison of groups on each day
using the Student’s t test, with no correction for multiple
comparisons. Antibody titers were also compared using
the Student’s t test, with no correction for multiple com-
parisons.
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